Key clinical point:
Major finding: The overall response rate was 53%.
Study details: A phase 1 trial involving 30 patients.
Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.
Source: Advani A et al. ASH 2017, Abstract 150.
Advani A et al. ASH 2017, Abstract 150.
This Week's Must Reads
LVADs as destination therapy, Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.
Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.
Anticoagulation linked to low BMD in children, Patel KN et al. Thrombosis & Hemostasis Societies of North America 2018, Poster 65.
New option for chronic graft vs. host, Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.
In myeloma, go for a third transplant, Garderet L et al. Biol Blood Marrow Transplant. 2018 Feb 3. doi: 10.1016/j.bbmt.2018.01.035
Must Reads in AML
Over half of refractory AML patients responded to combo, Advani A et al. ASH 2017, Abstract 150.
Characteristics of Early ARDS In Patients with AML, Leuk Lymphoma; ePub 2018 Feb 12; Van de Louw, et al
Tamibarotene vs. ATRA in APL, Source: Takeshita A et al. ASH 2017, abstract 642.
Outcomes in Older Transplant Patients with AML/MDS , Biol Blood Marrow Transplant; ePub 2017 Dec 27; Tsai, et al
Venetoclax Regimens Assessed in Patients with AML, Am J Hematol; ePub 2017 Dec 23; DiNardo, et al